Showing results (11-20 of 239) with videos related to
Sort By:
Pageof 24
International Pharmacopsychiatry|January 1, 1982
Psychopharmacology and Leonhard's classification of chronic schizophreniasT A Ban, W Guy, W H Wilson, et al.International Pharmacopsychiatry|January 1, 1980
A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophreniaJ P McEvoy, S Berney, W H Wilson, et al.Pharmacotherapy|January 1, 1983
A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatologyW Guy, J M McEvoy, T A Ban, et al.International Pharmacopsychiatry|January 1, 1980
Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical studyW M Petrie, J P McEvoy, W H Wilson, et al.International Pharmacopsychiatry|January 1, 1982
Viloxazine in the treatment of endogenous depression. A standard (amitriptyline) controlled clinical studyW M Petrie, T A Ban, W H Wilson, et al.International Pharmacopsychiatry|January 1, 1980
Mianserin: determination of therapeutic dose rangeW M Petrie, W H Wilson, T A Ban, et al.The Journal of Clinical Psychiatry|March 1, 1982
Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical studyJ P McEvoy, J Libiger, W H Wilson, et al.International Pharmacopsychiatry|January 1, 1982
A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressivesW Guy, T A Ban, J P McEvoy, et al.Acta Psiquiatrica Y Psicologica De America Latina|September 1, 1992
[Nosology, genetics, neurobiology, and psychopharmacology of schizophrenia]T A BanProgress in Neuro-Psychopharmacology|January 1, 1979
Adverse effects in maintenance treatment: practical and theoretical considerationsT A BanPageof 24